Abstract:OBJECTIVE:To explore the risks of long-term proton pump inhibitors (PPI) use.METHODS:A total of 79 study subjects were selected from patients seeking health care at outpatient gastroenterology clinic at Peking University People's Hospital during January 2011 to June 2013. Long-term PPI use was defined as taking PPI for at least one year. They were divided into study (n = 79) and control (n = 47) groups after matching for age and gender. The study group had 43 females and 36 males with an average age of (63 ± 10) years. And the control group had 28 females and 19 males with an average age of (63 ± 9) years. Data collected were demographic characteristics, clinical diagnosis, detailed dosing information of PPI. serum hemochrome, serum gastrin, vitamin B(12), serum iron, magnesium, calcium, copper, zinc, bone density of hip joint and lumbar vertebra L(1-4). Statistic analysis was performed with SPSS software (t and χ(2) test).RESULTS:The medium duration of PPI use was 3.07(1-15) years. Daily usage was a full or half amount of pharmaceutical directed dosage. Questionnaires regarding appetite, defecation, infection, otalgia change in long-term PPI use indicated:among them, 77(97.5%) cases had no appetite change and 2 (2.5%) improved. And 73 cases (92.4%) had no change or 2 cases improved (2.5%) in bowel movements habits while another 4 cases (5.1%) changed into loose stools. Lung or intestinal infection was not found. No case had an onset of otalgia related with PPI intake. Among PPI users, 14 cases (17.7%) appeared to have gastric polyps. T value of total bone density of hip and inter-hip was -0.93 ± 1.04 and -0.61 ± 0.91 respectively in the study group. And both were lower than those in the control group (-0.44 ± 1.12, -0.19 ± 0.94; t = -2.49, -2.35; P = 0.014, 0.021). No statistical differences existed in T value of neck of hip, as well as total T value and T value of each L(1-4) between study and control groups (all P > 0.05). Higher serum Mg compared to control group ((1.03 ± 0.08) vs (0.97 ± 0.07) mmol/L, t = 4.13, P = 0.000). No difference of serum calcium, copper, iron, zinc, vitamin B(12), folic acid and Hb,MCV,MCH between study and control groups (all P > 0.05). Higher serum gastrin versus normal range and controls were found in the study group ((108 ± 28) vs 100 vs (79 ± 26) ng/L, t = 2.56, 5.78; both P < 0.05). Taking manual routine dosage have higher hip and lumbar osteoporosis than half-dosage, and bone density decreased and normal bone density ratios are lower(all P < 0.05).CONCLUSIONS:Long-term use of PPI with small or average dosage may slightly decrease hip density and increase serum gastrin. However, there is little effect on vitamin B(12) and minerals.

Proton Pump Inhibitors Increase the Risk of Early Biliary Infection After Placement of Percutaneous Transhepatic Biliary Stents

Clinical analysis of factors associated with biliary tract infection after percutaneous biliary stent implantation for malignant biliary obstruction

Long-term Use of Proton Pump Inhibitors is Associated with an Increased Risk of Nonalcoholic Fatty Liver Disease

[Effects of Proton Pump Inhibitors on In-Stent Restenosis in Patients Receiving Clopidogrel: a Retrospective Analysis].

Risk factors for acute pancreatitis post percutaneous transhepatic biliary stenting in patients with distal malignant obstruction

Association of Proton Pump Inhibitor Prophylaxis on Clinical Outcome in Acute Ischemic Stroke in China: A Multicenter Retrospective Cohort Study.

Risk Prediction for Early Biliary Infection after Percutaneous Transhepatic Biliary Stent Placement in Malignant Biliary Obstruction

The Association of Long-Term Use of Proton Pump Inhibitors and Histamine H2 Receptor Antagonists with Clinical Complications in Patients with Severe Sepsis

Incidence and risk factors of pancreatitis in obstructive jaundice patients after percutaneous placement of self-expandable metallic stents

Risk Factors Associated with Acute Pancreatitis after Percutaneous Biliary Intervention: We Do Not Know Nearly Enough

Proton pump inhibitors use and risk of developing spontaneous bacterial peritonitis in cirrhotic patients: A systematic review and meta-analysis

Proton Pump Inhibitors and the Risk of Gallbladder Cancer: a Hospital-Based Case–control Study

Identification of risk factors for obstructive cholecystitis following placement of biliary stent in unresectable malignant biliary obstruction: a 5-year retrospective analysis in single center

[The Risks of Long-Term Proton Pump Inhibitors Use].

Association between preoperative proton pump inhibitor use and postoperative acute kidney injury in patients undergoing major surgery

Impact of Proton-pump Inhibitors on the Pharmacodynamic Effect and Clinical Outcomes in Patients Receiving Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: A Propensity Score Analysis

Analysis of critical complications and their risk factors after biliary stent implantation for malignant biliary obstruction

Risk factors for recurrent biliary obstruction following suprapapillary placement of a plastic stent as preoperative biliary drainage for perihilar biliary malignancy

Impact of proton pump inhibitors on the risk of small bowel or colorectal bleeding: A systematic review and meta-analysis

Proton pump inhibitors and odds of cholangiocarcinoma: A retrospective case‐control study

Association of proton pump inhibitor use with survival outcomes in patients with cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis.